TB Research

A <i>trans</i> -translation inhibitor kills <i>Mycobacterium tuberculosis</i> by targeting ribosomal protein bL12

Akanksha Varshney, John N. Alumasa, Amber Miller, Kenneth C. Keiler

bioRxiv (Cold Spring Harbor Laboratory) · 2025-06

Abstract

ABSTRACT New antibiotics with novel mechanisms of action are needed to treat infections by multidrug-resistant strains of Mycobacterium tuberculosis . Here, we show that KKL-1005, an anti-tubercular triazole-based molecule, binds to ribosomal protein bL12 and specifically inhibits the trans -translation ribosome rescue pathway, a process essential for the survival of M. tuberculosis. Our data demonstrate that KKL-1005 binds to the N terminal domain of bL12, both in vitro and in bacterial cells, and specifically inhibits trans -translation and not normal translation. These results suggest that tmRNA-SmpB interacts with bL12 differently from tRNA, and raise the possibility of developing antibiotics targeting bL12.

MeSH terms

  • Mycobacterium tuberculosis
  • Tuberculosis
  • Translation (biology)
  • Ribosomal RNA
  • Microbiology
  • Virology
  • Biology
  • Medicine